



### Application of Bundle Care in Critical Care Settings

Dr Saurabh Saigal

NAMSCON 2019

## Patient care-Complex

One of the cardinal principles of hospital care is that it should cause no harm to the patient

- Invasive procedures are being undertaken in greater numbers and with a higher degree of aggressiveness
- Patients with immuno-compromised status is increasing.
- Conditions for which patients require hospitalization weakens their resistance
- The hospital environment acts as a source of infection

• Micro-organisms endemic in hospitals are resistant to most antibiotics

### **Major HAIs**

- Catheter-associated urinary tract infection (CAUTI)
- Ventilator-associated pneumonia (VAP)
- Central line-related bloodstream infection (CRBSI)

### What is a bundle ?

- Grouping of best practices that have been individually proven to improve quality in an area of clinical practice
  - Simple
  - Basic
  - Tested and proven interventions that will improve patient outcomes
- They are generally so basic that they have been abandoned or lost in the intensity of high-tech devices.

# VAP Bundle CRBSI Bundle UTI Bundle

### **Sources of VAP pathogens**



### Definitions





Form Approved OMB No. 0920-0666 Exp. Date: 01/31/2021 www.cdc.gov/nhsn

#### Ventilator-Associated Event (VAE)

Page 1 of 4	*required for saving *required for completion												
Facility ID:	Event #:												
*Patient ID:	Social Security #:												
Secondary ID:	Medicare #:												
Patient Name, Last:	First: Middle:												
*Gender: F M Other	*Date of Birth:												
Ethnicity (Specify): Race (Specify):													
*Event Type: VAE	*Date of Event:												
Post-procedure VAE: Yes No Date of Procedure:													
NHSN Procedure Code:         ICD-10-PCS or CPT Procedure Code:													
*MDRO Infection Surveillance:													
□ இ正律業 兼和前任 P 正律記述 III IIII IIII IIII IIII IIIIIIIIIIII													
*Date Admitted to Facility:	*Location:												
* Location of Mechanical Ventilation Initiation:	*Date Initiated: / / APRV: Yes No												
Event Details													
	R)/A R												
*Specify Criteria Used:													
	STEP 1: VAC ([]1 REQUIRED)												
□ Daily min FiO₂ >====================================													
<sup>®</sup> after 2+ days of stable or decreasing daily m													
	STEP 2: IVAC												
Temperature > 38°C or < 36													
	AND												
A new antimicrob	ial agent(s) is started ාමත 🛠 🍿 🖬 🖛 🏟 🌐 කානා												
	STEP 3: PVAP												
$\Pi$ Criterion #1. Positive culture of one of the	following specimens, meeting quantitative or semi-quantitative thresholds as												
outlined in protocol	without requirement for purulent respiratory secretions:												
Endotracheal as													
	UR												
☐ Criterion #2: Purulent respiratory secre	tions <sup>©</sup> (defined in the protocol) <u>plus</u> organism(s) identified from one of the following specimens: <sup>©</sup>												
🛛 Sputum													
☐ Endotracheal as	pirate I Protected specimen brush												
	ne following positive tests (as outlined in the protocol):												
pleural fluid	Diagnostic test for <i>Legionella</i> species												
Lung histopatho	logy												
<sup>©</sup> collected after 2 days of mechanical ventilation	on and within +/- 2 days of onset of increase in FiO <sub>2</sub> or PEEP.												
*Secondary Bloodstream Infection: Yes No													
**Died: Yes No VAE Contr	buted to Death: Yes No												
Discharge Date: *Pathogen	s Identified: Yes No *If Yes, specify on pages 2-3												
Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)). Public reporting burden of this collection of information is estimated to average 28 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Ciliton Rd, MS D-74, Atlanta, GA 30333, ATTN, PRA (09200066)													

### How do we do it

Parameters	Day of Diagnosis	Day 3
Temperature (°C): • 36.1-38.4 • 38.5-38.9 • ≥39 or ≤36 WBC (colls/ml <sup>3</sup> × 1000):	0 points     1 point     2 points	<ul> <li>0 points</li> <li>1 point</li> <li>2 points</li> </ul>
<ul> <li>4-11</li> <li>4-11 plus bands &gt;5% or ≤4 or ≥11</li> <li>≤4 or ≥11 plus bands &gt;5%</li> </ul>	<ul> <li>0 points</li> <li>1 point</li> <li>2 points</li> </ul>	<ul><li>0 points</li><li>1 point</li><li>2 points</li></ul>
<ul> <li>Tracheal secretions or sputum:</li> <li>Absent</li> <li>Nonpurulent (no WBCs or &lt;10 WBC in sputum)</li> <li>Purulent (10-50 WBC in sputum)</li> </ul>	<ul><li>0 points</li><li>1 point</li><li>2 points</li></ul>	<ul><li>0 points</li><li>1 point</li><li>2 points</li></ul>
Oxygenation (PaO₂/FiO₂): • >240 • ARDS • ≤240 (with no ARDS)	<ul> <li>0 points</li> <li>1 point</li> <li>2 points</li> </ul>	<ul> <li>0 points</li> <li>1 point</li> <li>2 points</li> </ul>
CXR: • No new oroprogressive infiltrate • Diffuse (or patchy) infiltrate • Localized infiltrate	<ul> <li>0 points</li> <li>1 point</li> <li>2 points</li> </ul>	<ul> <li>0 points</li> <li>1 point</li> <li>2 points</li> </ul>
Progression of CXR (after 3 days): <ul> <li>Infiltrate clear at day 3</li> <li>No radiographic progression</li> <li>Radiographic progression (without CHF or ARDS)</li> </ul>	Do not calculate on day of diagnosis	<ul> <li>0 points</li> <li>1 point</li> <li>2 points</li> </ul>
Culture of sputum or tracheal aspirate: • No growth or culture between 1+and 2+ or <10 <sup>4</sup> • Growth 3+ to 4+ or ≥10 <sup>4</sup> or Growth 1+ to 2+ or <10 <sup>4</sup> and same bacteria on GS • Growth 3+ to 4+ or ≥10 <sup>4</sup> and same bacteria on GS	Do not calculate on day of diagnosis	0 points     1 point     2 points

CPIS>6 goes in favor of VAP or delta rise in CPIS score by 3

- We send samples
- We change antibiotics
- Wait for cultures and don't change over next 72 hours.
- Oxygenation worsening is most sensitive indicator

### **VAP Bundle**



Recommendation	Rationale	Intervention	Quality of evidence
Basic practices	Good evidence that the intervention decreases the average duration of	Use noninvasive positive pressure ventilation in selected populations <sup>57,58</sup>	High
	mechanical ventilation, length of	Manage patients without sedation whenever possible <sup>46,61</sup>	Moderate
	stay, mortality, and/or costs; benefits	Interrupt sedation daily <sup>62</sup>	High
	likely outweigh risks	Assess readiness to extubate daily <sup>47,66-68</sup>	High
		Perform spontaneous breathing trials with sedatives turned off <sup>48</sup>	High
		Facilitate early mobility <sup>49,70-75,78</sup>	Moderate
		Utilize endotracheal tubes with subglottic secretion drainage ports for patients expected to require greater than 48 or 72 hours of mechanical ventilation <sup>50</sup>	Moderate
		Change the ventilator circuit only if visibly soiled or malfunctioning <sup>88-91</sup>	High
		Elevate the head of the bed to 30°–45°84-86	Low <sup>a</sup>
Special approaches	Good evidence that the intervention improves outcomes but insufficient data available on possible risks	Selective oral or digestive decontamination <sup>93-96</sup>	$\mathrm{High}^\mathrm{b}$
	May lower VAP rates but insufficient	Regular oral care with chlorhexidine <sup>98,101-104</sup>	Moderate
	data to determine impact on dura-	Prophylactic probiotics <sup>111-114</sup>	Moderate
	tion of mechanical ventilation, length	Ultrathin polyurethane endotracheal tube cuffs <sup>120,121</sup>	Low
	of stay, or mortality	Automated control of endotracheal tube cuff pressure <sup>122,123</sup>	Low
		Saline instillation before tracheal suctioning <sup>124</sup>	Low
		Mechanical tooth brushing <sup>125,126</sup>	Low
Generally not	Lowers VAP rates but ample data sug-	Silver-coated endotracheal tubes <sup>127</sup>	Moderate
recommended	gest no impact on duration of me-	Kinetic beds <sup>128</sup>	Moderate
	chanical ventilation, length of stay, or mortality	Prone positioning <sup>87,129-134,c</sup>	Moderate
	No impact on VAP rates, average dura-	Stress ulcer prophylaxis <sup>135,136</sup>	Moderate
	tion of mechanical ventilation, length	Early tracheotomy <sup>137</sup>	High
	of stay, or mortality <sup>c</sup>	Monitoring residual gastric volumes <sup>138</sup>	Moderate
		Early parenteral nutrition <sup>139</sup>	Moderate
No recommendation	No impact on VAP rates or other pa- tient outcomes, unclear impact on costs	Closed/in-line endotracheal suctioning <sup>141-143</sup>	Moderate

TABLE 2. Summary of Recommendations for Preventing Ventilator-Associated Pneumonia (VAP) in Adult Patients

<sup>a</sup> There are very little data on head-of-bed elevation, but it is classified as a basic practice because of its simplicity, ubiquity, low cost, and potential benefit.

<sup>b</sup> There are abundant data on the benefits of digestive decontamination but insufficient data on the long-term impact of this strategy on Strategies to Prevent Ventilator-Associated Pneumonia in Acute NAMSCON 2019 Care Hospitals: 2014 Update antimicrobial resistance rates.

<sup>c</sup>?May be indicated for reasons other than VAP prevention.

### **CRBSI – Central Line Bundle**

#### ALL vascular access devices = BSI risk



Strategies to Prevent Central Line–Associated NAMSCON 2019 Bloodstream Infections in Acute Care Hospitals: 2014 Update

### **Patient Impact**

HAIs account for a large proportion of the harm to patients caused by health care<sup>c</sup>

Incidence rate estimated for hospitalized adult populations at risk for CLABSI.

CRBSIs are significant contributors to preventable hospital deaths.<sup>2</sup>

Real world evidence has demonstrated an increase in hospital resources - and associated cost - required to treat morbidities due to CRBSIs<sup>11-15</sup>



# Patients who contract CLABSI die<sup>7</sup>

Strategies to Prevent Central Line– Associated Bloodstream Infections in Acute Care Hospitals: 2014 Update

# The majority of CR-BSIs emanate from either the insertion site or the hub<sup>16-19</sup>

Organisms on the skin gain access to the bloodstream via migration along the external surface of the catheter or catheter hub; both important routes of catheter-related bloodstream infections<sup>17-21</sup>



Strategies to Prevent Central Line–Associated Bloodstream

14

### The use of bundles

Evidence-based recommendations and performance improvement initiatives or strategies are bundled together to improve compliance<sup>26</sup>

Central Line Insertion Bundles <sup>26-29</sup>	
Hand Hygiene	
Skin antisepsis using >0.5% chlorhexidine in alcohol solution	
Maximal sterile barrier precautions (Mask, cap, sterile gown, large sterile drape and sterile gloves)	
Avoid the femoral vein for CVC placement	

### **Barrier Precautions**







#### Full body sheet

#### 21-10-2019

**Maintenance includes many interventions** 

After catheter insertion, maintenance bundles have been proposed to ensure optimal catheter care<sup>29</sup>

### Maintenance Bundles<sup>26-29</sup> Assess need for catheter daily Perform hand hygiene before manipulation of IV system Dressing change recommendations and guidelines based on dressing type IV tubing administration set, secondary set and add-on device change guidelines based on medication or product infused

NAMSCON 2019

Disinfect IV access ports with appropriate disinfectant for a period of time



### Catheter Care

#### **Factors Predisposing to CRBSI**



#### **Factors Predisposing to CRBSI**



### Catheter care: is it correct ?



NAMSCON 2019

### Skin preparation

- Prepare clean skin with a >0.5% chlorhexidine preparation with alcohol IA
- If there is a contraindication to chlorhexidine, tincture of iodine, an iodophor, or 70% alcohol can be used as alternatives **IA**
- No comparison has been made between using chlorhexidine preparations with alcohol and povidone-iodine in alcohol to prepare clean skin. *Unresolved issue*
- No recommendation can be made for the safety or efficacy of chlorhexidine in infants aged <2 months. *Unresolved issue*

Strategies to Prevent Central Line–Associated Bloodstream Infections in Acute Care Hospitals: 2014 Update

NAMSCON 2019

#### • Recommendation Update [July 2017] Category I A

Chlorhexidine-impregnated dressings (with an FDA-cleared label) are recommended to protect the insertion site of short-term, non-tunnelled CVC

#### [Superseded 2011 Recommendation]

#### • Antimicrobial/Antiseptic Impregnated Catheters and Cuffs

Use a chlorhexidine/silver sulfadiazine or minocycline/ rifampin -impregnated CVC in patients whose catheter is expected to remain **in place >5 days** if, after successful implementation of a comprehensive strategy to reduce rates of CLABSI, the CLABSI rate is not decreasing

#### **Category IA**

#### • Antiseptic ointment

Use povidone iodine antiseptic ointment or bacitracin/ gramicidin/polymyxin B ointment at the haemodialysis catheter exit site after catheter insertion and at the end of each dialysis session only if this ointment does not interact with the material of the haemodialysis catheter per manufacturer's recommendation

#### Category IB

### Preventing Catheter-Associated Urinary Tract Infections CAUTI

### Why CA-UTI?

- Most common hospital-acquired infection
- 40% of all HAIs
- 12-25% of all hospitalized patients receive a urinary catheter
- Half of these found to not have valid indication
- Increased length of stay 0.5 1 day

### **Preventing CA-UTI**

1. Avoid unnecessary urinary catheters

2. Insert using aseptic technique

3. Maintain catheters based on recommended guidelines (daily care)

4. Review catheter necessity daily and remove promptly

### 1. Avoidance Strategies

- External condom catheters for appropriate male patients
- Intermittent catheterization multiple times per day
- Assessing urinary retention with bladder ultrasound

### 2. Insert urinary catheters using aseptic technique

- Utilize appropriate hand hygiene practice.
- Insert catheters using aseptic technique and sterile equipment, specifically using:
  - gloves, a drape, and sponges;
  - sterile or antiseptic solution for cleaning the urethral meatus; and
  - single-use packet of sterile lubricant jelly for insertion.
- Use as small a catheter as possible that is consistent with proper drainage, to minimize urethral trauma.

### 3. Maintain catheters based on recommended guidelines

- Maintain a sterile, continuously closed drainage system.
- Keep catheter properly secured to prevent movement and urethral traction.
- Keep collection bag below the level of the bladder at all times.
- Maintain unobstructed urine flow.
- Empty collection bag regularly .

### Errors

#### Wrongly placed urinary bag

#### **Catheter** -fixation





### 4. Daily review of necessity with prompt removal

"The duration of catheterization is the most important risk factor for development of infection." SHEA-IDSA Compendium, October 2008

- 74% of hospitals surveyed did not monitor catheter duration.
- 47% of patient days had no justification for continued catheterization.
- 41% of the time, physicians were unaware of patients inappropriately catheterized.

### AIIMS ICU 2018 data HAI

No. of patient days 2586	Degree of utilisation	HAI types	Rates
CVC days 1390	CVC utilisation rate-53.7%	VAP	67 per 1000 ventilator days Acceptable 10-30 very High
Ventilator days 1088	Ventilator utilisation rate-42%	CLABSI	16.56 per 1000 catheter days Acceptable <10; High
Urinary catheter days 2034	Urinary catheter utilisation rate- 78.65%	UTI	7.3 per 1000 catheter days Acceptable ;ok

# BED TURNOVER INTERVAL (25 days for a 10 bedded ICU)

- BTI= <u>available staffed bed days</u> –occupied bed days Total discharges/ deaths
- BTI =  $\frac{250-244}{43}$  = 0.13
  - \*Negative: over utilization Short positive: optimum utilization long positive : Under utilization

Dr Brahamam - Audit slides Dr Ekta Audit Slides



#### SAKET NAGAR, BHOPAL (M.P.) – 462020

27-5-19

	INFECTION CONTROL M	EASUI	RES			0	2/	1-	X	1	1	Que	10
C No		24	27-9	28-16	1	21	m	X	Ar	26	201	1	
5. INO		(D1)	18 (D2)	72 (D3)	96 (D4)	120 (D5)	141 (D6)	168 (D7)	192	100	1 -	1	-
1.	Bain's circuit to be plasma sterilized every 48 hours		N4	Na	4	×:			(D8)	2	47	4 4	
2.	Bain's circuit to be discarded after 7 days		N	red		2	1	5	S			0	1_
3.	Nebulizer- Prior to nebulizing ;dip in cidex for 30 minutes and then wash with water and then nebulize the patient		Ma	ical	4	×	7	P.	2	2	12		-
4.	Disposable Nebulizer set to be discarded after 3 days		Ma	604		*	T	T					-
5.	IV drip sets to be changed every 24 hours		2		4	×	7	7	-	- P			
6.	Blood administration set to be discarded after use		144	A1 //	i	~	510	2	~	~			
7.	Three ways, extension tubing's and syringes to be changed every 24 hours. Note if three ways contaminated with blood to be discarded immediately.		N	2		~	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	N	0	5			
8.	Whenever using lipid emulsion i.e. Propofol, Dexmetomidine change tubing, syringes and three ways immediately after use.	- 11 M 107 - 109	100	N19		~	170	~	x	x			
9.	The suction bottle to be plasma sterilized every 48 hours.		NY	L	/	~	1	5	10		1	1	1
10.	Yonkers suction to be replaced within 72 hours		L	hia	~	$\times$	-	~	1	2	1-	k	1
11.	Bed railings, all surface contact surroundings to be cleaned with Micro-clean- H three times daily.	-	Ma	L	· · · ·	1	T			1			
2.	Central line dressing to be inspected daily, the transparent dressing to be changed every 48 hours		L	Na	-	×		V A	x	x	-		1
3.	Catheter mount &HME to be changed every 48 hours		Neg	1	-F	1	-	F	5	in	T,	1	1
4.	Bed sheet to be changed if contaminated with blood urine & faeces.		1	•	+	~	5	+	5	X	4	-	T
5.	Laryngoscopes to be plasma sterilized Saturday		Ale	M.g.	4	×	-	C	x	N	201	T	. {
		* .	R	TB	- Ch	-6	The	17	IC.	T	h	IT	P

2

1

#### ICU

#### **CENTRAL LINE INSERTION PRACTICES ADHERENCE MONITORING FORM**

Section A. General information													
Facility ID Surveillance ID													
Patient ID Patient Name													
Date of insertion	·/ (	DD/MM/YY)	Event#										
Name of observer:													
Occupation of in Medical student Reason for inser	Occupation of inserter:												
<ul> <li>New indicati administratic</li> <li>Replace malf</li> <li>Suspected ce</li> </ul>	<ul> <li>New indication for central line (e.g., hemodynamic monitoring, fluid/medication administration, etc.)</li> <li>Replace malfunctioning central line Other (specify):</li></ul>												
Section B. Sum	mary of insertion	practices											
Inserter performe	ed hand hygiene pr	ior to central line ins	ertion?	Yes No									
Which of the fol	lowing sterile barri	ers were used:											
Mask	Sterile gown	Sterile gloves	Сар	Full body sterile drape									
Yes	Yes	Yes	Yes	Yes									
No	No	No	No	No									
Skin preparation Alcohol	(check all that app	ly) Chlorhexid	line1 gluconate	Povidone iodine									
Was skin prep ag	gent completely dry	v at time of first skin	puncture Yes	s No									
Insertion site: F	emoral Jugul	ar Subclavian	Umbilical	Other									

				S	ection A:	Gene	ral Inform	nation	-	-				
		170011	1.		Patient na	me V	amam	Kamb	hal	1				
Patient id Facility name	20190	reillance Ur	nit		Date of ad	mission	to surveilla	ince Unit	(dd/m	m/	(1)			
					Sectio	on B:D	aily chec	ks						
Date	Central	Wascent	tral	Signatur	Was the		Signatur	Was the	acce	55 p	ort scrubbe	ed with an	antisept	ic each tim
(dd/mm/yr)	line day	line revie for neces today	ewed ssity	e of day shift nurse	soiling, shift D dampening and nurse st loosening		During shift?	During the day shift?		Sign of day shift nurse	During the night shift?		Sign of night shift nutse	
	0	-	-	N	today?		np	T Yes		0	NP	- des	No	N
00/8,	DI	Yes	NO	the	Yes	NO	- nd	Tes	IN	io	-nt	Pres	No	N
d1/8	Da	Tes	No	-7	Yes	No	8	T Yes	DN	0	0	Yes	No	
In Inc.		Res	No	pild.	Yes	No		Yes	IN	0		Yes	No	-
10119		Yes	No	0	Yes	No		Ves		0		Ves	No	
		Yes	No		Yes	No		Yes		10		Yes	No	
		Yes	No		Yes	No		Yes	0	10		Yes	No	
		Yes	No		Yes	No		Yes	- 1	10		Yes	NO	
		Yes	No		Yes	No		Yes	-	10		- Yes	NO	
		Yes	No		Yes	No		Yes		VO		- Yes	NO	
		TYes	No		Yes	NO		Yes		NO.		- 105	NO	
		_ Yes	No		Yes	NO		Yes	1	800		- Tes	No	
		Yes	No		Yes	No		Yes	1-1	NO.		- Tes		
		Yes	No		Yes	NO		Yes	-	NO.		- tes		
		Yes	No		Yes	NO		res		10			No	
		Voc	NO		Yes	NO		Yes		80				

### Future what we can do

Table 2	Care	bundle	compliance	

	Component																	
	1. pro	e.g. ophy	DV1 Iaxis	5	2. e.g. sedation hold				З. pro	3. e.g. GU prophylaxis				4. e.g. head of bed				
Patient	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4		
Day 1	Y	Υ	Y	Y	Ν	Ν	Ν	Ν	Ν	Ν	Y	Y	Y	Ν	Y	Y		
Day 2	Υ	Υ	Υ	Y	Ν	Ν	Ν	Ν	Ν	Ν	Υ	Υ	Υ	Ν	Υ	Υ		
Day 3	Υ	Ν	Υ	Υ	Ν	Ν	Ν	Ν	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ		
Day 4	Υ	Υ	Υ	Υ	Υ	Υ	Ν	Ν	Υ	Ν	Υ	Υ	Υ	Υ	Ν	Ν		
Day 5	Υ	Ν	Υ	Υ	Υ	Υ	Ν	Ν	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ		
Day 6	Υ	Υ	Υ	Ν	Υ	Ν	Ν	Ν	Ν	Ν	Υ	Υ	Υ	Υ	Υ	Υ		
Day 7	Υ	Υ	Υ	Υ	Υ	Ν	Υ	Ν	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Ν		
Day 8	Y	Υ	Υ	Υ	Y	Ν	Y	Ν	Y	Υ	Υ	Υ	Y	Υ	Υ	Υ		



DVT, deep vein thrombosis; GU, gastric ulceration; Y, compliance; N, non-compliance.

#### Infection rates of various wards can be displayed

### SUMMARY

- Instead of jumping on antibiotics we should focus more attention on following these bundles
- An educational session alone, without an associated behavioural strategy, is unlikely to induce profound behavioural changes.
- It should be kept in mind that, to engage an individual in a particular behaviour and improve compliance, we need to act on predisposing factors (knowledge, perceptions, and beliefs) to favour the access to new processes or technologies and to continually reinforce the behaviour by feedback

### **TEAM work**



### AVERAGE LENGTH OF STAY IN ICU

- Indicates Efficiency of health care services and depends upon the
- **1.** Characteristics of the patient
- 2. Disease characteristics
- 3. Habits of doctors and staff
- 4. Hospital infections

Dr Brahamam- Audit slides Dr Ekta –Audit Slides

### **BED TURNOVER RATIO**

• No of patients cured/ treated for a bed during the period.

BTR = <u>No of discharges / transfers / deaths</u> Avg bed count

Dr Brahamam- Audit slides Dr Ekta – Audit Slides